Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
IMMX · Why this verdict
Why Immix Biopharma (IMMX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Immix Biopharma offers a high-asymmetry speculative setup with 66% analyst-implied upside, but a quality score well below the engine's floor, a pattern of earnings misses, and elevated volatility mean the position remains a binary, high-risk bet on clinical progress.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Sentiment notes show a 91% analyst-implied upside, translating into a favorable asymmetry ratio of 4.41 (66.2% upside against 15% downside) at the current price. Sentiment breakdown | If this upside case holds, analyst-implied upside should stay elevated over the next 12 months. | Tripped→Stable |
| CounterAnalyst targets on speculative biotech names with only 1 beat in the last 4 quarters can be highly volatile and are frequently revised down following a negative clinical or earnings surprise, which would collapse this asymmetry. | ||
Quality notes show the company is cash-burning with negative free cash flow, no competitive moat, and a weak Piotroski F-Score of 2 out of 9, pulling the overall quality score to 1.2, well below the engine's 4.0 floor. Quality breakdown | If this quality concern holds, the Piotroski F-Score should remain at 2 out of 9 or lower over the next 12 months. | →Stable |
| CounterPre-commercial biotechs are structurally expected to burn cash and score poorly on traditional quality metrics like Piotroski, so a low reading here may simply reflect the business stage rather than genuine risk. | ||
The company has missed earnings estimates in 3 of the last 4 quarters with an average surprise of -31.39%, indicating a pattern of underperforming consensus expectations. Earnings | If this execution concern holds, the pattern of earnings misses should continue over the next several quarters. | →Stable |
| CounterEarnings misses for a clinical-stage biotech are largely driven by R&D spend timing rather than commercial execution, making the miss framing largely disconnected from the actual investment thesis around clinical progress. | ||
Risk notes show implied volatility at 117%, reflecting the market's expectation of large price swings tied to binary clinical or regulatory catalysts. Risk breakdown | If this catalyst-driven volatility read is accurate, implied volatility should remain elevated as clinical catalysts approach. | →Stable |
| CounterSustained high implied volatility with no resolving catalyst can also just bleed option value over time without any corresponding price movement, hurting anyone positioned around the volatility. | ||
The engine's momentum gate passed narrowly at 5.5 against a 4.5 threshold, with a soft warning that the reading sits right at the boundary the engine treats as needing continued monitoring. Engine gate (passed) | If momentum stays constructive, the score should hold at or above 5.5 over the next 12 months. | →Stable |
| CounterA momentum reading that just barely clears its threshold provides limited confidence and could easily fall back below the bar on normal price volatility. | ||
Sentiment notes show a 91% analyst-implied upside, translating into a favorable asymmetry ratio of 4.41 (66.2% upside against 15% downside) at the current price.
Tripped→StableSentiment breakdown
- Expectation
- If this upside case holds, analyst-implied upside should stay elevated over the next 12 months.
CounterAnalyst targets on speculative biotech names with only 1 beat in the last 4 quarters can be highly volatile and are frequently revised down following a negative clinical or earnings surprise, which would collapse this asymmetry.
Quality notes show the company is cash-burning with negative free cash flow, no competitive moat, and a weak Piotroski F-Score of 2 out of 9, pulling the overall quality score to 1.2, well below the engine's 4.0 floor.
→StableQuality breakdown
- Expectation
- If this quality concern holds, the Piotroski F-Score should remain at 2 out of 9 or lower over the next 12 months.
CounterPre-commercial biotechs are structurally expected to burn cash and score poorly on traditional quality metrics like Piotroski, so a low reading here may simply reflect the business stage rather than genuine risk.
The company has missed earnings estimates in 3 of the last 4 quarters with an average surprise of -31.39%, indicating a pattern of underperforming consensus expectations.
→StableEarnings
- Expectation
- If this execution concern holds, the pattern of earnings misses should continue over the next several quarters.
CounterEarnings misses for a clinical-stage biotech are largely driven by R&D spend timing rather than commercial execution, making the miss framing largely disconnected from the actual investment thesis around clinical progress.
Risk notes show implied volatility at 117%, reflecting the market's expectation of large price swings tied to binary clinical or regulatory catalysts.
→StableRisk breakdown
- Expectation
- If this catalyst-driven volatility read is accurate, implied volatility should remain elevated as clinical catalysts approach.
CounterSustained high implied volatility with no resolving catalyst can also just bleed option value over time without any corresponding price movement, hurting anyone positioned around the volatility.
The engine's momentum gate passed narrowly at 5.5 against a 4.5 threshold, with a soft warning that the reading sits right at the boundary the engine treats as needing continued monitoring.
→StableEngine gate (passed)
- Expectation
- If momentum stays constructive, the score should hold at or above 5.5 over the next 12 months.
CounterA momentum reading that just barely clears its threshold provides limited confidence and could easily fall back below the bar on normal price volatility.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 2.4 |
| OBV | 1.9 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.7 |
- ▸Analyst upside: 93%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.0 |
| growth rank | 5.0 |
Technical
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.3 |
| support resistance | 5.4 |
| 52w position | 6.9 |
| gap | 6.0 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.3 |
| days to cover | 6.8 |
| volatility | 0.0 |
| beta | 10.0 |
| debt equity | 10.0 |
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- ASYMMETRY:4.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.2<4.5
Warning (0)
none
Reward-to-Risk
4.51
Upside
+67.7%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 52 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.2<4.5 outcome against Value at 9.0 and asymmetric R:R of 4.51.
The strongest dimensions are Value at 9.0, Insider at 7.3, and Sentiment at 6.8; the weakest are Quality at 1.6, Catalyst at 1.7, and Momentum at 3.2. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 4.51 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Analyst Upside AsymmetryTripped
Trip ifAnalyst-implied upside falls below 20% as price targets are cut.
- P2Quality Below Floor
Trip ifPiotroski F-Score rises above 4 out of 9 for 2 consecutive quarters as cash burn narrows.
- P3Earnings Miss Pattern
Trip ifEPS surprise rises above 0% in at least 3 of the next 4 quarters.
- P4Elevated Options Volatility
Trip ifImplied volatility falls below 60% while no material clinical catalyst has occurred.
- P5Momentum Passed Near Threshold
Trip ifMomentum score falls below 4.5 for 2 consecutive quarters.